DiaMedica Therapeutics (NASDAQ:DMAC) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a sell rating to a strong sell rating in a report issued on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Stock Performance

DiaMedica Therapeutics stock opened at $6.32 on Friday. DiaMedica Therapeutics has a fifty-two week low of $3.47 and a fifty-two week high of $10.42. The stock has a market cap of $340.52 million, a P/E ratio of -8.90 and a beta of 0.99. The firm’s fifty day moving average price is $6.88 and its 200-day moving average price is $7.56.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, analysts predict that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DMAC. Cooperman Leon G lifted its stake in DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock worth $22,463,000 after purchasing an additional 1,619,761 shares during the last quarter. Corient IA LLC bought a new position in shares of DiaMedica Therapeutics during the third quarter valued at about $910,000. Paragon Associates & Paragon Associates II Joint Venture grew its stake in shares of DiaMedica Therapeutics by 34.6% during the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after buying an additional 225,000 shares during the last quarter. Members Wealth LLC purchased a new position in shares of DiaMedica Therapeutics in the fourth quarter worth about $864,000. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at about $687,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.